NACFC Recap

I had a good time at the NACFC this week and met a bunch of great people. It was especially exciting to run into Emily Schaller and Jerry Cahill as they are both two people that I admire in the CF community because of their commitment to exercise and no excuses attitude.

In case you missed them, here are some cool announcements to come out of the conference:

Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin

Data Presentations at the NACFC Highlight Denufosol’s Novel Mechanism of Action

Gilead's Cayston(R) Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study

Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection

Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results

Innovotech's Biofilm Test Shows Significant Differences in Antibiotic Choices for Cystic Fibrosis Patients Compared to Conventional Testing

Vertex Pharmaceuticals Initiates Clinical Trial to Evaluate Combination Regimens of VX-770 and VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis -Primary endpoints of safety, tolerability and effect on CFTR function as measured by sweat chloride

ARIKACE(TM) Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients Data Presented at the North American Cystic Fibrosis Conference

Discovery Labs Announces Presentation & Key Results of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis at the North American Cystic Fibrosis Conference